Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.53 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | SNCA | P37840 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quinoline SCHEMBL28065955 | 0.78 | ALDH1A1 (0.57) | MAPTCYP1A2CYP2C19HTTKDM4E | |
| SCHEMBL5790265 | 0.75 | DAO (0.53) | DAOATAD2MAPTSNCACYP1A2 | |
| SCHEMBL2118566 | 0.75 | DAO (0.53) | DAOATAD2MAPTSNCAHRH4 | |
| SCHEMBL29997480 | 0.75 | ATAD2 (0.62) | DAOATAD2MAPTSNCACYP1A2 | |
| SCHEMBL4641753 | 0.75 | ATAD2 (0.62) | DAOATAD2MAPTSNCACYP1A2 | |
| SCHEMBL25248466 | 0.75 | DAO (0.53) | DAOATAD2MAPTSNCAHRH4 | |
| SCHEMBL1472999 | 0.75 | DAO (0.62) | DAOATAD2MAPTSNCAHRH4 | |
| SCHEMBL12615150 | 0.75 | DAO (0.53) | DAOATAD2MAPTSNCAHRH4 | |
| SCHEMBL27738193 | 0.73 | DAO (0.51) | DAOATAD2MAPTSNCACYP1A2 | |
| SCHEMBL13469140 | 0.71 | ATAD2 (0.53) | DAOATAD2MAPTSNCAHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107043395-A | A kind of synthetic method of azaindole substituted boracic acid class compound | 江苏常州酞青新材料科技有限公司 | 2017-08-15 | — | — | CN | claimed |
| CN-103626767-A | Azaindole with regionselectivity and synthetic method thereof | WUXI APPTEC CO LTD | 2014-03-12 | — | — | CN | claimed |
| CN-114341135-A | Estrogen-related receptor alpha (ERR alpha) modulators | 领先制药控股公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-107043395-A | A kind of synthetic method of azaindole substituted boracic acid class compound | 江苏常州酞青新材料科技有限公司 | 2017-08-15 | — | — | CN | disclosed |
| CN-104619708-A | Azaindole derivatives | TAKEDA PHARMACEUTICAL | 2015-05-13 | — | — | CN | disclosed |
| CN-104411706-A | Imidazolone derivatives, pharmaceutical compositions and uses thereof | BEIJING FORELANDPHARMA CO LTD | 2015-03-11 | — | — | CN | disclosed |
| CN-103748076-A | ROR gamma T inhibitors | MERCK SHARP & DOHME | 2014-04-23 | — | — | CN | disclosed |
| US-7517872-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-14 | — | — | US | disclosed |
| US-20080206191-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-08-28 | — | — | US | disclosed |
| WO-2008103637-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-28 | — | — | WO | disclosed |
| US-6075037-A | Endothelin receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2000-06-13 | — | — | US | disclosed |
| EP-0763035-A4 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 1997-10-01 | — | — | EP | disclosed |
| EP-0763035-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-03-19 | — | — | EP | disclosed |
| WO-1995033748-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080206191-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | DAO 1000/4885ATAD2 4633/4885MAPT 4368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.